SCHEMBL25214972

SCHEMBL25214972

Cc1ccc(S(=O)(=O)Oc2cc(OS(=O)(=O)c3ccc(C)cc3)c(C(=O)N3CCc4cc(CN(C)C)ccc4C3)c(OCC3CCCCC3)c2C)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
QRFPR Q96P65 8/20 0.42
KCNH2 Q12809 2/20 0.39
CYP2D6 P10635 1/20 0.38
KCNE1 P15382 1/20 0.38
SCN5A Q14524 1/20 0.38
HTT P42858 2/20 0.37
LMNA P02545 2/20 0.37
HPGD P15428 2/20 0.37
ALDH1A1 P00352 1/20 0.37
POLB P06746 1/20 0.35
NR4A1 P22736 1/20 0.35
ESR2 Q92731 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
MEN1 O00255 1/20 0.35
MAPT P10636 1/20 0.35
RECQL P46063 1/20 0.35
KMT2A Q03164 1/20 0.35
CD4 P01730 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35
RORC P51449 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25248403 0.86 HSP90AA1 (0.40) ALDH1A1CD4ACACB
SCHEMBL25221649 0.82 HSP90AA1 (0.42) LMNAALDH1A1MAPTACACB
SCHEMBL30301554 0.81 QRFPR (0.48) QRFPRKCNH2CYP2D6KCNE1SCN5A
SCHEMBL30368441 0.80 QRFPR (0.42) QRFPRKCNH2CYP2D6KCNE1SCN5A
SCHEMBL25212540 0.77 F2 (0.36) KCNH2MEN1KMT2ACD4
SCHEMBL30462427 0.77 ALDH1A1 (0.33) LMNAALDH1A1POLBESR2TDP1
SCHEMBL25234807 0.77 ALDH1A1 (0.33) LMNAALDH1A1POLBESR2TDP1
SCHEMBL30368071 0.76 ENPP1 (0.41) CYP2D6ALDH1A1MEN1KMT2ACD4
SCHEMBL25669112 0.76 ENPP1 (0.41) CYP2D6ALDH1A1MEN1KMT2ACD4
SCHEMBL25215919 0.76 F2 (0.38) CYP2D6HTTLMNAALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12552758-B2 Inhibitors of MLH1 and/or PMS2 for cancer treatment Neophore Limited (GB) 2026-02-17 US disclosed
US-20230183197-A1 INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT Neophore Limited (GB) 2023-06-15 US disclosed
EP-4157463-A1 INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT Neophore Limited (GB) 2023-04-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12552758-B2 Inhibitors of MLH1 and/or PMS2 for cancer treatment MSH2, PMS2, MSH6 QRFPR 3732/4885KCNH2 1582/4885CYP2D6 607/4885
US-20230183197-A1 INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT MSH2, PMS2, MSH6 QRFPR 2617/4885KCNH2 3606/4885CYP2D6 1613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.